Canagliflozin Improves HF Symptoms in Fully Remote Trial Canagliflozin Improves HF Symptoms in Fully Remote Trial
The benefit of the SGLT2 inhibitor was consistent, regardless of ejection fraction and presence or absence of type 2 diabetes, in the decentralized CHIEF-HF trial.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
More News: Canagliflozin | Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Invokana | SGLT2 Inhibitors